Here's Why DexCom (DXCM) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Dexcom Stock A Buy Now?
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past.
S&P 500 Gains and Losses Today: Amazon Stock Surges as Cloud Business Boosts Earnings; DexCom Drops
Shares of an e-commerce and cloud computing powerhouse delivered big gains on the final day of October, while a medical device maker came under pressure after an executive provided an underwhelming outlook for 2026 sales growth.
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised
DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.
DexCom Stock Is the Worst Performer in the S&P 500. Here's Why.
The maker of diabetes technology posts better-than-expected revenue but shares are falling.
Dexcom shares extend fall over 2026 growth concerns
Dexcom shares tumbled 12% in premarket trading on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations.
DexCom, Inc. (DXCM) Q3 2025 Earnings Call Transcript
DexCom, Inc. ( DXCM ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Sean Christensen - Vice President of Finance and Investor Relations Jacob Leach - Interim CEO, President & COO Jereme Sylvain - Executive VP, CFO & Chief Accounting Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Matthew Taylor - Jefferies LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division David Roman - Goldman Sachs Group, Inc., Research Division Marie Thibault - BTIG, LLC, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Michael Polark - Wolfe Research, LLC Jayson Bedford - Raymond James & Associates, Inc., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Michael Kratky - Leerink Partners LLC, Research Division Richard Newitter - Truist Securities, Inc., Research Division Joshua Jennings - TD Cowen, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Presentation Operator Ladies and gentlemen, welcome to the DexCom Third Quarter 2025 Earnings Release Conference Call.
DexCom (DXCM) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DexCom (DXCM) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.45 per share a year ago.
Insights Into DexCom (DXCM) Q3: Wall Street Projections for Key Metrics
Beyond analysts' top-and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.
DexCom, Inc. (DXCM) Presents At Baird Global Healthcare Conference 2025 Transcript
DexCom, Inc. (NASDAQ:DXCM ) Baird Global Healthcare Conference 2025 September 10, 2025 2:00 PM EDT Company Participants Sean Christensen - Vice President of Finance and Investor Relations Conference Call Participants Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Presentation Jeffrey Johnson Senior Research Analyst Next presentation this afternoon is from DexCom, a leader in developing and commercializing continuous glucose monitoring systems for people with diabetes and I'm sure in the future beyond diabetes.
